<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38424126</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>29</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>IL-6 and IL-17 as potential links between pre-existing hypertension and long-term COVID sequelae in patients undergoing hemodialysis: a multicenter cross-sectional study.</ArticleTitle><Pagination><StartPage>4968</StartPage><MedlinePgn>4968</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4968</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-54930-z</ELocationID><Abstract><AbstractText>Long COVID, characterized by persistent symptoms following acute infection, poses a significant health challenge, particularly for patients with pre-existing chronic conditions such as hypertension. We hypothesized that an increase in the production of interleukins (IL)-6 and IL-17 could serve as a potential mechanism linking pre-existing uncontrolled blood pressure (BP) to the occurrence of long-term COVID sequelae in patients undergoing hemodialysis (HD). This cross-sectional study examined serum IL-6 and IL-17 levels in 80 patients undergoing HD, considering preinfection BP, the presence of long-term COVID sequelae, and the time interval after acute COVID-19 infection, which was either 5 or 10&#xa0;months. Controlled BP was defined as a 3-month average pre-dialysis BP&#x2009;&lt;&#x2009;140/90&#xa0;mmHg and post-dialysis&#x2009;&lt;&#x2009;130/80&#xa0;mmHg. The findings suggest that the prevalence of long-term COVID sequelae was significantly higher in patients with uncontrolled BP than in the BP-controlled group. Both IL-6 and IL-17 concentrations were also significantly higher in patients with uncontrolled BP compared with the BP-controlled group. The patients with long-term COVID sequelae had higher IL-6 and IL-17 values than the fully recovered patients at both time points, but their concentrations decreased significantly over time. Further research and prospective studies are warranted to validate these findings.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stepanova</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1070-3602</Identifier><AffiliationInfo><Affiliation>Department of Nephrology and Dialysis, State Institution "Institute of Nephrology of the National Academy of Medical Sciences", Kyiv, Ukraine. nmstep88@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Driianska</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-2586-5532</Identifier><AffiliationInfo><Affiliation>Laboratory of Immunology, State Institution "Institute of Nephrology of the National Academy of Medical Sciences", Kyiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rysyev</LastName><ForeName>Andriy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dialysis Medical Center LLC "Link-Medital", Odesa, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostapenko</LastName><ForeName>Tetyana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Dialysis Medical Center LLC "Nephrocenter", Zaporizhzhia, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalinina</LastName><ForeName>Nataliia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology, State Institution "Institute of Nephrology of the National Academy of Medical Sciences", Kyiv, Ukraine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508717">IL17A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>1</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>29</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38424126</ArticleId><ArticleId IdType="pmc">PMC10904824</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-54930-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-54930-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang F, et al. Risk factors for mortality in hemodialysis patients with COVID-19: A systematic review and meta-analysis. Ren. fail. 2021;43:1394&#x2013;1407. doi: 10.1080/0886022X.2021.1986408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2021.1986408</ArticleId><ArticleId IdType="pmc">PMC8510603</ArticleId><ArticleId IdType="pubmed">34629011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu CM, et al. COVID-19 among US dialysis patients: Risk factors and outcomes from a national dialysis provider. Am. J. Kidney. Dis. 2021;77:748&#x2013;756.e1. doi: 10.1053/j.ajkd.2021.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2021.01.003</ArticleId><ArticleId IdType="pmc">PMC7816961</ArticleId><ArticleId IdType="pubmed">33465417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk S, et al. The longitudinal evolution of post-COVID-19 outcomes among hemodialysis patients in Turkey. Kidney Int. Rep. 2022;7:1393&#x2013;1405. doi: 10.1016/j.ekir.2022.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2022.03.017</ArticleId><ArticleId IdType="pmc">PMC8949692</ArticleId><ArticleId IdType="pubmed">35350104</ArticleId></ArticleIdList></Reference><Reference><Citation>Och A, et al. Persistent post-COVID-19 syndrome in hemodialyzed patients-A longitudinal cohort study from the north of Poland. J. Clin. Med. 2022;10:4451. doi: 10.3390/jcm10194451.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10194451</ArticleId><ArticleId IdType="pmc">PMC8509624</ArticleId><ArticleId IdType="pubmed">34640471</ArticleId></ArticleIdList></Reference><Reference><Citation>Stepanova N, et al. High-density lipoproteins and clinical outcomes of COVID-19 in hemodialysis patients: A multicenter, propensity-score matched case-control study. Ukr. J. Nephrol. Dial. 2022;73:22&#x2013;30.</Citation></Reference><Reference><Citation>Matsumoto C, et al. Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19. Hypertens. Res. 2022;46:601&#x2013;619. doi: 10.1038/s41440-022-01145-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-022-01145-2</ArticleId><ArticleId IdType="pmc">PMC9793823</ArticleId><ArticleId IdType="pubmed">36575228</ArticleId></ArticleIdList></Reference><Reference><Citation>Majidpoor J, Mortezaee K. Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomed. Pharmacother. 2022;145:112419. doi: 10.1016/j.biopha.2021.112419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112419</ArticleId><ArticleId IdType="pmc">PMC8585600</ArticleId><ArticleId IdType="pubmed">34781146</ArticleId></ArticleIdList></Reference><Reference><Citation>Martonik D, Parfieniuk-Kowerda A, Rogalska M, Flisiak R. The role of Th17 response in COVID-19. Cells. 2021;10:1550. doi: 10.3390/cells10061550.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10061550</ArticleId><ArticleId IdType="pmc">PMC8235311</ArticleId><ArticleId IdType="pubmed">34205262</ArticleId></ArticleIdList></Reference><Reference><Citation>McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end-organ damage. Circ Res. 2015;116:1022&#x2013;1033. doi: 10.1161/CIRCRESAHA.116.303697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.303697</ArticleId><ArticleId IdType="pmc">PMC4535695</ArticleId><ArticleId IdType="pubmed">25767287</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert M, Miossec P. Effects of Interleukin 17 on the cardiovascular system. Autoimmun Rev. 2017;16:984&#x2013;991. doi: 10.1016/j.autrev.2017.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.07.009</ArticleId><ArticleId IdType="pubmed">28705781</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf;, C., et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep. Med. 3, 100663 10.1016/j.xcrm.2022.100663 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelmann N, Dantzer R, Khandaker GM. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. 2021;131:105295. doi: 10.1016/j.psyneuen.2021.105295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2021.105295</ArticleId><ArticleId IdType="pmc">PMC8172271</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId></ArticleIdList></Reference><Reference><Citation>Corr&#xea;a HL, et al. Phosphate and IL-10 concentration as predictors of long-covid in hemodialysis patients: A Brazilian study. Front Immunol. 2022;13:1006076. doi: 10.3389/fimmu.2022.1006076.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1006076</ArticleId><ArticleId IdType="pmc">PMC9562993</ArticleId><ArticleId IdType="pubmed">36248863</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheppard JP, et al. Association between blood pressure control and coronavirus disease 2019 outcomes in 45 418 symptomatic patients with hypertension: An observational cohort study. Hypertension. 2021;77:846&#x2013;855. doi: 10.1161/HYPERTENSIONAHA.120.16472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.16472</ArticleId><ArticleId IdType="pmc">PMC7884248</ArticleId><ArticleId IdType="pubmed">33325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, et al. Hypertension as an independent risk factor for severity and mortality in patients with COVID-19: A retrospective study. Postgrad. Med. J. 2021;98:515&#x2013;522. doi: 10.1136/postgradmedj-2021-140674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2021-140674</ArticleId><ArticleId IdType="pubmed">37066501</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallamaci F, et al. Treatment-resistant hypertension in the hemodialysis population: A 44-h ambulatory blood pressure monitoring-based study. J. Hypertens. 2020;38:1849&#x2013;1856. doi: 10.1097/HJH.0000000000002448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000002448</ArticleId><ArticleId IdType="pubmed">32649620</ArticleId></ArticleIdList></Reference><Reference><Citation>Gy&#xf6;ngy&#xf6;si M, et al. Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: A joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. Cardiovasc. Res. 2023;119:336&#x2013;356. doi: 10.1093/cvr/cvac115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvac115</ArticleId><ArticleId IdType="pmc">PMC9384470</ArticleId><ArticleId IdType="pubmed">35875883</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin JX, et al. Increased interleukin-6 is associated with long COVID-19: A systematic review and meta-analysis. Infect. Dis. Poverty. 2023;12:43. doi: 10.1186/s40249-023-01086-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-023-01086-z</ArticleId><ArticleId IdType="pmc">PMC10123579</ArticleId><ArticleId IdType="pubmed">37095536</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz MAF, et al. Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome. Front. Cell. Infect. Microbiol. 2022;12:922422. doi: 10.3389/fcimb.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, E. S., et al. Cytokine deficiencies in patients with long-COVID. J. Clin. Cell. Immunol.13, 672. PMC9894377 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9894377</ArticleId><ArticleId IdType="pubmed">36742994</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim HK, Al-Rubaye HT, Al-Hadrawi DS, Almulla AF, Maes M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol. Psychiatry. 2023;28:564&#x2013;578. doi: 10.1038/s41380-022-01836-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01836-9</ArticleId><ArticleId IdType="pmc">PMC9589528</ArticleId><ArticleId IdType="pubmed">36280755</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobo, G., Lindholm, B., &amp; Stenvinkel, P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol. Dial. Transplant. 33, iii35-iii40 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168801</ArticleId><ArticleId IdType="pubmed">30281126</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito, P., et al. Effects of Different Dialysis Strategies on Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients with COVID-19: A Randomized Trial. J. Clin. Med. 10, 1383 10.3390/jcm10071383 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8037035</ArticleId><ArticleId IdType="pubmed">33808205</ArticleId></ArticleIdList></Reference><Reference><Citation>MacRae C, Mercer SW, Guthrie B, Henderson D. Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. Br. J. Gen. Pract. 2021;71:e243&#x2013;e249. doi: 10.3399/bjgp20X714125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp20X714125</ArticleId><ArticleId IdType="pmc">PMC7888754</ArticleId><ArticleId IdType="pubmed">33558333</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisowska, K., A., Storoniak, H., D&#x119;bska-&#x15a;lizie&#x144;, A. T cell subpopulations and cytokine levels in hemodialysis patients. Hum. Immunol.83, 134&#x2013;143 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34802797</ArticleId></ArticleIdList></Reference><Reference><Citation>Prietl B, et al. Chronic inflammation might protect hemodialysis patients from severe COVID-19. Front. Immunol. 2022;13:821818. doi: 10.3389/fimmu.2022.821818.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.821818</ArticleId><ArticleId IdType="pmc">PMC8901184</ArticleId><ArticleId IdType="pubmed">35265078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciceri, P., et al. Cytokine and Chemokine Retention Profile in COVID-19 Patients with Chronic Kidney Disease. Toxins (Basel). 14, 673. 10.3390/toxins14100673 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9611576</ArticleId><ArticleId IdType="pubmed">36287942</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Rodr&#xed;guez, E., et al. Inflammatory cytokines as uremic toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son". Toxins (Basel). 9, 114. 10.3390/toxins9040114 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408188</ArticleId><ArticleId IdType="pubmed">28333114</ArticleId></ArticleIdList></Reference><Reference><Citation>Claro, L., M., et al. The impact of uremic toxicity induced inflammatory response on the cardiovascular burden in chronic kidney disease. Toxins (Basel). 10, 384 10.3390/toxins10100384 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6215310</ArticleId><ArticleId IdType="pubmed">30249039</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, G. Immune Dysfunction in Uremia 2020. Toxins (Basel). 12, 439. 10.3390/toxins12070439 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404977</ArticleId><ArticleId IdType="pubmed">32635646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazur T, et al. Chronic inflammation and progression of chronic kidney disease in patients with type 2 diabetes. Ukr. J. Nephr. Dial. 2021;72:36&#x2013;43. doi: 10.31450/ukrjnd.4(72).2021.05.</Citation><ArticleIdList><ArticleId IdType="doi">10.31450/ukrjnd.4(72).2021.05</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanase, D., M., et al. Arterial hypertension and interleukins: potential therapeutic target or future diagnostic marker? Int. J. Hypertens. 2019, 3159283. 10.1155/2019/3159283 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6521461</ArticleId><ArticleId IdType="pubmed">31186952</ArticleId></ArticleIdList></Reference><Reference><Citation>McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end-organ damage. Circ. Res. 2015;116:1022&#x2013;1033. doi: 10.1161/CIRCRESAHA.116.303697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.303697</ArticleId><ArticleId IdType="pmc">PMC4535695</ArticleId><ArticleId IdType="pubmed">25767287</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacurari, M., Kafoury, R., Tchounwou, P. B., Ndebele, K. The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int. J. Inflam. 2014, 689360 10.1155/2014/689360 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3997861</ArticleId><ArticleId IdType="pubmed">24804145</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhamad SA, Ugusman A, Kumar J, Skiba D, Hamid AA, Aminuddin A. COVID-19 and hypertension: The what, the why, and the how. Front. Physiol. 2021;12:665064. doi: 10.3389/fphys.2021.665064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2021.665064</ArticleId><ArticleId IdType="pmc">PMC8126692</ArticleId><ArticleId IdType="pubmed">34012410</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, et al. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-&#x3ba;B pathway. Elife. 2021;10:e68563. doi: 10.7554/eLife.68563.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.68563</ArticleId><ArticleId IdType="pmc">PMC8709575</ArticleId><ArticleId IdType="pubmed">34866574</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SK, et al. Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: Implications for COVID-19 pathogenesis and consequences. Eur. Respir. J. 2021;57:2003730. doi: 10.1183/13993003.03730-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03730-2020</ArticleId><ArticleId IdType="pmc">PMC7830336</ArticleId><ArticleId IdType="pubmed">33479113</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DL, et al. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am. J. Physiol. Heart Circ. Physiol. 2006;290:H935&#x2013;940. doi: 10.1152/ajpheart.00708.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00708.2005</ArticleId><ArticleId IdType="pubmed">16284237</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhur MS, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500&#x2013;507. doi: 10.1161/HYPERTENSIONAHA.109.145094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.109.145094</ArticleId><ArticleId IdType="pmc">PMC2819301</ArticleId><ArticleId IdType="pubmed">20038749</ArticleId></ArticleIdList></Reference><Reference><Citation>Luther JM, et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension. 2006;48:1050&#x2013;1057. doi: 10.1161/01.HYP.0000248135.97380.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000248135.97380.76</ArticleId><ArticleId IdType="pubmed">17043157</ArticleId></ArticleIdList></Reference><Reference><Citation>Orejudo, M., et al. Interleukin 17A participates in renal inflammation associated to experimental and human hypertension. Front. Pharmacol. 10, 1015 10.3389/fphar.2019.01015 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6753390</ArticleId><ArticleId IdType="pubmed">31572188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo, G., Volpe, M., Savoia, C. Endothelial dysfunction in hypertension: Current concepts and clinical implications. Front. Med. (Lausanne). 8, 798958 10.3389/fmed.2021.798958 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8811286</ArticleId><ArticleId IdType="pubmed">35127755</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: An overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol. Sin. 2022;44:695&#x2013;709. doi: 10.1038/s41401-022-00998-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-022-00998-0</ArticleId><ArticleId IdType="pmc">PMC9574180</ArticleId><ArticleId IdType="pubmed">36253560</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim HK, Al-Rubaye HT, Al-Hadrawi DS, Almulla AF, Maes M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: A proof of concept and mechanism study. Mol. Psychiatry. 2023;28:564&#x2013;578. doi: 10.1038/s41380-022-01836-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01836-9</ArticleId><ArticleId IdType="pmc">PMC9589528</ArticleId><ArticleId IdType="pubmed">36280755</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S, et al. Long COVID 19 syndrome: Is it related to microcirculation and endothelial dysfunction? insights from TUN-EndCOV study. Front. Cardiovasc. Med. 2021;8:745758. doi: 10.3389/fcvm.2021.745758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.745758</ArticleId><ArticleId IdType="pmc">PMC8670225</ArticleId><ArticleId IdType="pubmed">34917659</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect. Dis. (Lond) 2021;53:737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>